Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
Mpm Asset Management Llc	4.43M	2023-09-07	4.43M	0	Shares	67.01B
Stepstone Group Lp	761.28K	2023-08-14	761.28K	0	Shares	11.53M
Tcg Crossover Management, Llc	584.96K	2023-08-14	584.96K	0	Shares	8.86M
72 Investment Holdings, Llc	509.02K	2023-08-14	509.02K	0	Shares	7.71M
Nan Fung Group Holdings Ltd	49.08K	2023-08-11	73.58K	-24.50K	Shares	743.10K
Chi Advisors Llc	0	2023-08-22	56.37K	-56.37K	Shares	0

NASDAQ:TRDA

Entrada Therapeutics, Inc.

Last Close

17.10

26/07 20:00

Market Cap

584.36M

Beta: -

Volume Today

78.61K

Avg: 47.59K

PE Ratio

−24.93

PFCF: 4.35

Institutional trades

Institutional Ownership

Current holdings institutionals